Supplemental online content for:

Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response

Margaret M. Kozak, MD; Clare E. Jacobson, BA; Rie von Eyben, MS; Erqi L. Pollom, MD, MS; Melinda Telli, MD; and Kathleen C. Horst, MD

J Natl Compr Canc Netw 2018;16(7):845–850

eFigure 1: Overall Survival by Breast Cancer Subtype and Pathologic Complete Response
**eFigure 1.** Overall survival by breast cancer subtype and pCR: (A) HR-positive/HER2-negative, (B) HR-positive/HER2-positive, (C) HR-negative/HER2-positive, and (D) triple-negative breast cancer.

Abbreviations: HR, hormone receptor; pCR, pathologic complete response.